BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
PRKCA
,
Response to oxidative stress
,
Ischemia
,
Lymphocyte
,
Early pregnancy factor
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
ba 2
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
No genes found
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
No biogroups found
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
Pro-B BAF-3 cells overexpressing MPL[W515L] and treated with JAK2 inhibitor INCB18424
Drug Matrix In Vivo Toxicogenomic Study - Rat Kidney [Codelink]
Drug Matrix In Vivo Toxicogenomic Study - Rat Heart [Codelink]
Drug Matrix In Vivo Toxicogenomic Study - Rat Liver [Codelink]
Drug Matrix In Vivo Toxicogenomic Study - Rat Kidney [Affymetrix]
Explore Curated Studies Results
Literature
Most Relevant Literature
Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5.
Evasion of Neutralizing Antibody Response by the SARS-CoV-2 BA.2.75 Variant.
Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike.
Virological features and pathogenicity of SARS-CoV-2 Omicron BA.2.
Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
A Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and O…
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA Va…
A Preliminary Exploratory Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Particip…
Clinical Trial of COVID-19 Vaccine(SARS-CoV-2 Variant(Omicron BA.5) mRNA Vaccine) in Participants Ag…
Tofacitinib Citrate Topical Gel 3.2% FDA BA Bridging Study
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ